Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
517 hedge funds and large institutions have $18.4B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2021 Q1 according to their latest regulatory filings, with 95 funds opening new positions, 188 increasing their positions, 188 reducing their positions, and 70 closing their positions.
36% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 70
35% more funds holding in top 10
Funds holding in top 10: 23 → 31 (+8)
24% more call options, than puts
Call options by funds: $207M | Put options by funds: $167M
24% more capital invested
Capital invested by funds: $14.9B → $18.4B (+$3.55B)
4% more funds holding
Funds holding: 497 → 517 (+20)
0% more repeat investments, than reductions
Existing positions increased: 188 | Existing positions reduced: 188
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$110M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$108M |
| 3 |
BlackRock
New York
|
+$98.7M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$67.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$58.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$134M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$131M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$93.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$87.3M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$71.7M |
HZNP Hedge Fund Activity: Q1 2021 in Review
517 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2021, worth a combined $18.4B — up 24% from $14.9B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new HZNP positions and 70 closed out — a net gain of 25 holders — while 188 added to existing stakes and 188 trimmed.
The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $110M. The largest seller was Renaissance Technologies, cutting an estimated $134M.
- 517 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2021, up from 497 in Q4 2020.
- Funds reported $18.4B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2021, up 24% quarter-over-quarter.
- 95 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2021 and 70 closed out, a net change of +25 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2021 was Waddell & Reed Financial, an estimated $110M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2021 was Renaissance Technologies, an estimated $134M sold.
Based on aggregated 13F filings for Q1 2021.